OverviewSuggest Edit

GeoVax is a biotechnology company specializing in the creation, development, and commercialization of human vaccines to combat HIV/AIDS. Designed for predominant HIV virus subtypes in the developed world, our most advanced vaccine candidate is designed for use in uninfected people to protect them from AIDS should they be exposed to the HIV-1 virus.
TypePublic
Founded2001
HQSmyrna, US
Websitegeovax.com

Latest Updates

Employees (est.) (Dec 2018)8(+15%)

Key People/Management at GeoVax

Robert T. McNally

Robert T. McNally

President & CEO
Mark W. Reynolds

Mark W. Reynolds

CFO
Harriet L. Robinson

Harriet L. Robinson

CSO
Show more

GeoVax Office Locations

GeoVax has an office in Smyrna
Smyrna, US (HQ)
1900 Lake Park Dr SE
Show all (1)

GeoVax Financials and Metrics

GeoVax Revenue

USD

Net income (FY, 2018)

(2.6m)

EBIT (FY, 2018)

(2.6m)

Market capitalization (8-Oct-2018)

4.1m

Cash (31-Dec-2018)

259.7k
GeoVax's current market capitalization is $4.1 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

General and administrative expense

1.8m1.8m1.4m2.1m1.2m1.6m

R&D expense

2.9m1.8m1.7m2.0m2.0m1.9m

Operating expense total

4.7m3.6m3.1m4.1m3.2m3.5m

EBIT

(2.3m)(2.7m)(2.7m)(3.3m)(2.2m)(2.6m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018Q3, 2018

General and administrative expense

316.5k371.8k344.9k411.8k401.4k364.9k335.9k906.5k344.8k220.7k292.7k352.2k357.2k359.2k459.0k

R&D expense

879.1k402.9k516.2k425.5k403.6k384.7k378.5k438.0k397.6k683.9k551.8k518.1k487.0k372.2k557.7k

Operating expense total

1.2m774.7k861.1k837.3k805.1k749.5k714.5k1.3m742.4k904.6k844.5k870.3k844.2k731.4k1.0m

EBIT

(191.3k)(617.3k)(680.6k)(515.2k)(701.6k)(678.1k)(621.3k)(1.3m)(576.1k)(464.5k)(548.7k)(518.2k)(622.9k)(638.1k)(667.3k)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

2.5m1.1m1.1m454.0k312.7k259.7k

Inventories

43.6k44.5k56.6k62.3k

Current Assets

2.7m1.2m1.2m544.4k448.1k619.7k

PP&E

120.2k96.7k83.6k54.8k31.2k11.4k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

1.7m2.0m1.4m862.2k3.1m2.5m1.8m669.5k215.1k511.1k166.7k822.6k571.2k191.0k511.2k

Current Assets

1.8m2.0m1.4m926.4k3.2m2.6m1.9m709.0k258.8k602.2k240.4k933.6k802.3k339.1k596.2k

PP&E

106.4k103.6k113.2k105.3k98.1k90.8k76.4k69.2k62.0k52.3k45.4k26.2k21.2k16.3k

Total Assets

2.0m2.2m1.5m1.1m3.4m2.7m2.0m796.5k339.1k675.2k303.7k990.0k839.5k371.4k623.5k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(2.3m)(2.7m)(2.7m)(3.3m)(2.2m)(2.6m)

Depreciation and Amortization

78.9k69.0k28.9k28.8k28.0k19.8k

Inventories

(1.3k)(934.0)(12.1k)(5.6k)

Accounts Payable

(14.7k)(125.3k)(60.0k)242.9k441.4k553.1k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(1.4m)(615.9k)(1.3m)(1.8m)(700.5k)(1.4m)(619.9k)(1.3m)(1.9m)(464.2k)(548.3k)(1.1m)(621.8k)(1.3m)(1.9m)

Depreciation and Amortization

52.7k16.4k32.7k50.0k14.5k7.2k14.4k13.8k5.0k9.9k14.9k

Accounts Payable

(101.5k)(77.0k)(74.9k)(142.1k)45.9k(5.9k)42.5k39.5k53.2k33.5k150.9k281.7k107.1k252.8k486.4k

Cash From Operating Activities

(872.0k)(503.5k)(1.1m)(1.6m)(1.3m)(629.1k)(1.2m)(761.2k)(381.6k)(761.8k)(1.0m)
USDY, 2018

Financial Leverage

-0.6 x
Show all financial metrics

GeoVax Online and Social Media Presence

Embed Graph

GeoVax News and Updates

GeoVax Announces Publication of Lassa Fever Vaccine Study Results

100% Single-Dose Protection Observed in Lethal Challenge ModelAtlanta, GA - (NewMediaWire) - September 04, 2019 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today announced publication of its article entitled “A Single Dose of Modified Vaccinia Ankara Ex…

GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress

ATLANTA, Aug. 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human immunotherapies and vaccines, today announced its financial results for the quarter ended June 30, 2019 and provided an update on its corporate development progr…

GeoVax Issues Shareholder Update Letter

Updates Provided on Financial Status and Development ProgramsAtlanta, GA - (NewMediaWire) - August 02, 2019 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines and immunotherapies, today issued an update letter to its shareholders and other interested parties. I…

GeoVax Addresses WHO Declaration of Ebola Outbreak as Global Public Health Emergency

Company Offers Novel Ebola Vaccine for Public Health Use…GratisAtlanta, GA - (NewMediaWire) - July 30, 2019 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines and immunotherapies, today responded to the World Health Organization’s (WHO) recent declaration of th…

GeoVax Announces 100% Protection Data from Marburg Virus Vaccine Study

Study Data Adds to Similar Efficacy Previously Reported for GeoVax’s Ebola and Lassa Fever VaccinesAtlanta, GA - (NewMediaWire) - July 29, 2019 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines and immunotherapies, today announced positive results (100% protec…

GeoVax Presents HIV Vaccine Study Data

Presentation Made at the 10th International AIDS Society Conference on HIV ScienceAtlanta, GA - (NewMediaWire) - July 24, 2019 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in developing human vaccines, announced today that Harriet L. Robinson, PhD, Chief Scientific Of…
Show more

GeoVax Frequently Asked Questions

  • When was GeoVax founded?

    GeoVax was founded in 2001.

  • Who are GeoVax key executives?

    GeoVax's key executives are Robert T. McNally, Mark W. Reynolds and Harriet L. Robinson.

  • How many employees does GeoVax have?

    GeoVax has 8 employees.

  • Who are GeoVax competitors?

    Competitors of GeoVax include Biogen, Inovio Pharmaceuticals and MyoKardia.

  • Where is GeoVax headquarters?

    GeoVax headquarters is located at 1900 Lake Park Dr SE, Smyrna.

  • Where are GeoVax offices?

    GeoVax has an office in Smyrna.

  • How many offices does GeoVax have?

    GeoVax has 1 office.